|

Rina-S Clinical Trials

5 actively recruiting trials across 4 locations

No change since June 2026

Also known as: GEN1184, PRO1184, Rinatabart Sesutecan, Rinatabart sesutecan

Pipeline

Phase 2: 2Phase 3: 2Phase 1/2: 1

Top Sponsors

  • Genmab5

Indications

  • Cancer5
  • Endometrial Cancer2
  • Lung Cancer2
  • Primary Refractory Ovarian Cancer1
  • Platinum Sensitive Ovarian Cancer (PSOC)1

Phoenix, Arizona2 trials

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

USOR HonorHealth

Phase 1/2
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

HonorHealth Research Inst

Phase 3

Fountain Valley, California1 trial

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

Compassionate Cancer Care Center

Phase 2

Miami, Florida1 trial

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

Mt. Sinai Comprehensive Cancer Center

Phase 3

Grand Rapids, Michigan1 trial

Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers

START Midwest

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.